Literature DB >> 15167204

Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction.

Anna M Thøgersen1, Stefan Söderberg, Jan-Håkan Jansson, Gösta Dahlén, Kurt Boman, Torbjörn K Nilsson, Bernt Lindahl, Lars Weinehall, Hans Stenlund, Vivan Lundberg, Owe Johnson, Bo Ahrén, Göran Hallmans.   

Abstract

BACKGROUND: The summarized importance of haemostatic and metabolic variables (insulin, lipids including lipoprotein (a) [Lp(a)] and leptin) in predicting first myocardial infarction, as well as possible interactions among these variables, have not been reported.
DESIGN: A prospective case-control study nested within the Northern Sweden Health and Disease Cohort.
METHODS: Sixty-two men diagnosed with a first myocardial infarction were sex- and age-matched with 124 controls. Conditional logistic regression was conducted including established risk factors, plasma levels of plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) mass concentration, von Willebrand factor, insulin, proinsulin, specific insulin, apolipoprotein A-I (apo A-I), Lp(a), and leptin. Interaction analysis was also performed for tPA, apo A-I, Lp(a), leptin and proinsulin.
RESULTS: Smoking, low plasma levels of apo A-I and high plasma levels of cholesterol, Lp(a), tPA, PAI-1, proinsulin and leptin were associated with myocardial infarction in univariate conditional logistic regression analysis. High tPA [odds ratio (OR), 21.3; 95% confidence interval (CI), 2.04-222] and Lp(a) (OR, 7.21; 95% CI, 1.31-39.8) and low apo A-I (OR, 0.15; 95% CI, 0.02-0.93) remained significant risk determinants in multivariate analysis with smoking habits, body mass index, hypertension, cholesterol, and diabetes included as covariates. There were non-significant synergic interactions between high Lp(a) and leptin and tPA, respectively, and between high Lp(a) and low apo A-I.
CONCLUSION: Plasma levels of tPA, Lp(a), and apo A-I are independently associated with subsequent development of a first myocardial infarction in men.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15167204     DOI: 10.1097/01.hjr.0000116824.84388.a2

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  18 in total

Review 1.  Leptin and cardiovascular disease: response to therapeutic interventions.

Authors:  Kwang Kon Koh; Sang Min Park; Michael J Quon
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

2.  Leptinemia is Associated With Peripheral Artery Disease.

Authors:  Greg J Zahner; Joel L Ramirez; Kimberly A Spaulding; Sukaynah A Khetani; Warren J Gasper; Carl Grunfeld; Nancy K Hills; Anne L Schafer; S Marlene Grenon
Journal:  J Surg Res       Date:  2019-02-06       Impact factor: 2.192

3.  Novel locus for fibrinogen in 3' region of LEPR gene in island population of Vis (Croatia).

Authors:  Željka Tomas; Matea Zajc Petranović; Tatjana Škarić-Jurić; Ana Barešić; Marijana Peričić Salihović; Nina Smolej Narančić
Journal:  J Hum Genet       Date:  2014-10-09       Impact factor: 3.172

4.  Beneficial effects of leptin treatment in a setting of cardiac dysfunction induced by transverse aortic constriction in mouse.

Authors:  Nieves Gómez-Hurtado; Alejandro Domínguez-Rodríguez; Philippe Mateo; María Fernández-Velasco; Almudena Val-Blasco; Rafael Aizpún; Jessica Sabourin; Ana María Gómez; Jean-Pierre Benitah; Carmen Delgado
Journal:  J Physiol       Date:  2017-05-23       Impact factor: 5.182

5.  Are common leptin promoter polymorphisms associated with restenosis after coronary stenting?

Authors:  Julie Anna Bienertová-Vasků; Ota Hlinomaz; Anna Vasků
Journal:  Heart Vessels       Date:  2007-09-20       Impact factor: 2.037

6.  Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells.

Authors:  Prachi Singh; Timothy E Peterson; Kara R Barber; Fatima Sert Kuniyoshi; Andrus Jensen; Michal Hoffmann; Abu S M Shamsuzzaman; Virend K Somers
Journal:  Biochem Biophys Res Commun       Date:  2010-01-05       Impact factor: 3.575

Review 7.  Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease.

Authors:  Seth S Martin; Atif Qasim; Muredach P Reilly
Journal:  J Am Coll Cardiol       Date:  2008-10-07       Impact factor: 24.094

Review 8.  Differential Role of Leptin and Adiponectin in Cardiovascular System.

Authors:  C M Ghantous; Z Azrak; S Hanache; W Abou-Kheir; A Zeidan
Journal:  Int J Endocrinol       Date:  2015-05-03       Impact factor: 3.257

9.  The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.

Authors:  J Danesh; S Erqou; M Walker; S G Thompson; R Tipping; C Ford; S Pressel; G Walldius; I Jungner; A R Folsom; L E Chambless; M Knuiman; P H Whincup; S G Wannamethee; R W Morris; J Willeit; S Kiechl; P Santer; A Mayr; N Wald; S Ebrahim; D A Lawlor; J W G Yarnell; J Gallacher; E Casiglia; V Tikhonoff; P J Nietert; S E Sutherland; D L Bachman; J E Keil; M Cushman; B M Psaty; R P Tracy; A Tybjaerg-Hansen; B G Nordestgaard; R Frikke-Schmidt; S Giampaoli; L Palmieri; S Panico; D Vanuzzo; L Pilotto; L Simons; J McCallum; Y Friedlander; F G R Fowkes; A J Lee; F B Smith; J Taylor; J Guralnik; C Phillips; R Wallace; D Blazer; K T Khaw; J H Jansson; C Donfrancesco; V Salomaa; K Harald; P Jousilahti; E Vartiainen; M Woodward; R B D'Agostino; P A Wolf; R S Vasan; M J Pencina; E M Bladbjerg; T Jorgensen; L Moller; J Jespersen; R Dankner; A Chetrit; F Lubin; A Rosengren; L Wilhelmsen; G Lappas; H Eriksson; C Bjorkelund; P Cremer; D Nagel; R Tilvis; T Strandberg; B Rodriguez; L M Bouter; R J Heine; J M Dekker; G Nijpels; C D A Stehouwer; E Rimm; J Pai; S Sato; H Iso; A Kitamura; H Noda; U Goldbourt; V Salomaa; J T Salonen; K Nyyssönen; T-P Tuomainen; D Deeg; J L Poppelaars; T Meade; J Cooper; B Hedblad; G Berglund; G Engstrom; A Döring; W Koenig; C Meisinger; W Mraz; L Kuller; R Selmer; A Tverdal; W Nystad; R Gillum; M Mussolino; S Hankinson; J Manson; B De Stavola; C Knottenbelt; J A Cooper; K A Bauer; R D Rosenberg; S Sato; Y Naito; I Holme; H Nakagawa; H Miura; P Ducimetiere; X Jouven; C Crespo; M Garcia-Palmieri; P Amouyel; D Arveiler; A Evans; J Ferrieres; H Schulte; G Assmann; J Shepherd; C Packard; N Sattar; B Cantin; B Lamarche; J-P Després; G R Dagenais; E Barrett-Connor; D Wingard; R Bettencourt; V Gudnason; T Aspelund; G Sigurdsson; B Thorsson; M Trevisan; J Witteman; I Kardys; M Breteler; A Hofman; H Tunstall-Pedoe; R Tavendale; G D O Lowe; Y Ben-Shlomo; B V Howard; Y Zhang; L Best; J Umans; A Onat; T W Meade; I Njolstad; E Mathiesen; M L Lochen; T Wilsgaard; J M Gaziano; M Stampfer; P Ridker; H Ulmer; G Diem; H Concin; F Rodeghiero; A Tosetto; E Brunner; M Shipley; J Buring; S M Cobbe; I Ford; M Robertson; Y He; A M Ibanez; E J M Feskens; D Kromhout; R Collins; E Di Angelantonio; S Kaptoge; S Lewington; L Orfei; L Pennells; P Perry; K Ray; N Sarwar; M Scherman; A Thompson; S Watson; F Wensley; I R White; A M Wood
Journal:  Eur J Epidemiol       Date:  2007-09-18       Impact factor: 8.082

10.  Leptin predicts diabetes but not cardiovascular disease: results from a large prospective study in an elderly population.

Authors:  Paul Welsh; Heather M Murray; Brendan M Buckley; Anton J M de Craen; Ian Ford; J Wouter Jukema; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G J Westendorp; James Shepherd; Naveed Sattar
Journal:  Diabetes Care       Date:  2008-11-10       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.